-
Mashup Score: 0Understanding the Pathophysiology of Rett Syndrome: Setting the Stage for Future Developments - 1 year(s) ago
Why are investigational therapies targeting MECP2 or downstream pathways? Find out from Rett syndrome experts.
Source: MedscapeCategories: Latest Headlines, NeurologyTweet
-
Mashup Score: 0
Current antifibrotic agents are not curative for idiopathic pulmonary fibrosis (IPF). Moreover, existing preclinical models do not fully replicate the human …
Source: YouTubeCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
Current antifibrotic agents are not curative for idiopathic pulmonary fibrosis (IPF). Moreover, existing preclinical models do not fully replicate the human …
Source: YouTubeCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
Current antifibrotic agents are not curative for idiopathic pulmonary fibrosis (IPF). Moreover, existing preclinical models do not fully replicate the human …
Source: YouTubeCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0
Join 3 experts in the field while they discuss anti-thrombocytopenic therapies for patients with liver disease ahead of surgery.
Source: MedscapeCategories: Latest Headlines, SurgeryTweet
-
Mashup Score: 0Bronchiolitis therapies and misadventures - PubMed - 2 year(s) ago
Viral bronchiolitis, which is most commonly caused by an infection with the respiratory syncytial virus (RSV), can lead to respiratory difficulties in young children which may require hospitalization. Despite years of research and medical trials, the mainstay of bronchiolitis treatment remains suppo …
Source: PubMedCategories: Latest Headlines, PulmonologyTweet
-
Mashup Score: 0Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A trial led by clinicians at @LombardiCancer showed a remarkable 20% advantage in the 2-year overall #survival rate for people with advanced #melanoma who first received #immunotherapy (72% SR) versus those who initially got targeted #therapies (52% SR): https://t.co/2R7N4TeoXS https://t.co/ypHHFu3Ao6
-
-
Mashup Score: 3Wolters Kluwer Health - 2 year(s) ago
JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…
Source: lww.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A trial led by clinicians at @LombardiCancer showed a remarkable 20% advantage in the 2-year overall #survival rate for people with advanced #melanoma who first received #immunotherapy (72% SR) versus those who initially got targeted #therapies (52% SR): https://t.co/2R7N4TeoXS https://t.co/afsQZhKIJN
-
-
Mashup Score: 2Drug Development Dashboard - Friends of Cancer Research - 2 year(s) ago
Friends has created a series of interactive dashboards as a tool to gain data driven insights into the landscape of oncology drug development and FDA drug approvals. The data in these dashboards are compiled from online publicly available data sources and are regularly updated. Dashboard Functionality Hover your mouse over the figures on the dashboards…
Source: Friends of Cancer ResearchCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Patients with COPD in England initiating SITT had significantly better adherence and persistence compared with MITT initiators. These improvements continued at least 18 months following treatment initiation.
Source: PubMedCategories: Latest Headlines, PulmonologyTweet
📍 Why are investigational #therapies targeting MECP2 or downstream pathways? Find out from Rett syndrome experts. #RettSyndrome #MedEd #CME #MedTwitter #NeuroTwitter 📝 https://t.co/upej2MTylK https://t.co/uTU3CWsXYJ